Thalidomide for prevention of camrelizumab‐induced reactive cutaneous capillary endothelial proliferation

Abstract

Objectives:The study evaluated the efficacy of thalidomide in prevention of camrelizumab-induced reactive cutaneous capillary endothelial proliferation (RCCEP).Methods: In this study, patients treated with camrelizumab plus thalidomide or camrelizumab alone were included. The occurrences, onset time, severity of RCCEP and the adverse effect of thalidomide were analysed.Results: A total of 19 patients were enrolled. The incidence of RCCEP in thalidomide group (2/9, 22.2%) was significantly lower than that in camrelizumab group (8/10, 80%). The median onset time of RCCEP was 5 weeks and 4 weeks respectively.The adverse events of thalidomide were mild, and no treatment-associated interruption was observed.Conclusions: Thalidomide showed a promising in prevention of the RCCEP in patients receiving camrelizumab therapy with an acceptable safety profile.

Comparison of thalidomide versus apatinib for prevention of camrelizumab-induced reactive cutaneous capillary endothelial proliferation: a retrospective study

“…There was no consensus on the optimal dose and therapy duration of thalidomide in the treatment of vascular diseases. Our previous report demonstrated thalidomide response to a low dose 50mg/day in prevention RCCEP [8] , and this study supported the result that low dose thalidomide therapy was an effective option. The most common adverse effect was fatigue, followed by constipation, oedema and rash.…”

“…As an anti-angiogenic agent, apatinib had been used to treat RCCEP [6] , however, the high price and kinds of adverse effects limited its use [7] . As our previous study had shown that thalidomide is effective for prevention the RCCEP [8] , hence, we conducted a retrospective study to compare the clinical benefits of thalidomide and apatinib in prevention the RCCEP in patients receiving camrelizumab therapy.…”

A pilot study of camrelizumab with docetaxel and cisplatin for the first line treatment in recurrent/metastatic oral squamous cell carcinoma

“…Several studies have reported that irAEs are potentially associated with tumor response in patients receiving immune checkpoint blockade. 20 RCCEP, a special and most common irAE only observed in patients treated with camrelizumab, was a skin lesion manifested as a red spot or nodules that tended to rupture and bleed. 21 Wang et al 22 reported that RCCEP occurrence was positively associated with better mPFS, mOS, and ORR of camrelizumab in patients with advanced hepatocellular carcinoma.…”

“…Several studies have reported that irAEs are potentially associated with tumor response in patients receiving immune checkpoint blockade 20 . RCCEP, a special and most common irAE only observed in patients treated with camrelizumab, was a skin lesion manifested as a red spot or nodules that tended to rupture and bleed 21 .…”

Predicting Outcome in Combination Treatment of TACE and Camrelizumab for Advanced Hepatocellular carcinoma: Tumor Hypervascularity and Reactive Cutaneous Capillary Endothelial Proliferation

“… 14 , 15 Carrelizhu-related adverse events (AES) are widely considered as predictive markers for disease control and survival of patients with advanced HCC, especially RCCEP, which has been found in previous studies. 16 , 17 In this study, we tried to investigate the efficacy of TACE combined with carrelizumab in the treatment of advanced HCC, so as to determine the utility of vascular distribution and RCCEP as robust predictors, so as to select the potential benefit patients of TACE combined with carrelizumab according to these factors.…”